The overall probability for the development of a relapse was found to be 48.7% (95% CI: 40.9-56.5)(Figure1A). 23 patients (30.3%) died during the study period with a median survival of 9.6 months (range: 1.6-45). In the studied population the overall survival probability was found to...
Even with all these improvements, primary resistance to initial treatment and disease relapse remain huge unmet need in the treatment of AML. The majority of AML patients still eventually succumb to the disease. We still have a long way to further improve the survival of the AML patients, thus...
We observed a significant reduction in risk of non-relapse mortality (NRM) over time (HR = 0.34, 95% CI 0.12–0.98; P = 0.05), the 4-year NRM estimate decreased from 20% in 2005–2008 to 7% in 2012–2016 (P = 0.02) and an increase in survival after relapse. There...
“Based on the single-agent activity of quizartinib as well as the improved overall survival, the lower cumulative incidence of relapse, the long duration of these remissions, and the deeper remissions when combined with standard intensive chemotherapy that were achieved in the QuANTUM-First stud...
Byrd JC, Mrózek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) presented in par...
“I think we are going to continue to push the survival curves up in incremental fashion.” Moving forward, Stone said that prospective clinical trials are needed to ensure the novel agents are used in the appropriate patients and situations. “We have to be careful about using [new drugs] ...
AML中国诊疗指南AML部分.ppt,非移植患者10年生存率达37% N=202 43% 37% 总生存概率 1.0 0.8 0.6 0.4 0.2 0.0 时间 (年) 0 2 4 6 8 10 12 14 Eur J Haematol 2007; 78(6):477-486. 目前三十一页\总数五十五页\编于十点 非移植患者10年无复发生存率达32% N=195 40% 32% 无复发
Post-remission or remission continuation therapy (called consolidation therapy in the past).After you have achieved remission, this therapy aims to kill any remaining leukemia cells so the cancer doesn’t come back (relapse). In some cases, you may not be able to have post-remission therapy. ...
The main choice of treatment to reach a full remission and hampered chance of relapse is chemotherapy which itself is accompanied by alloHSCT. However, the prognosis of refractory/relapsed AML has remained poor and its 5-year survival rate is around 27% [2,3]. Unfortunately, the treatment st...
Owing to the limited expansion capacity of CD33 CAR-NK cells, long-term survival was achieved in only one patient. We hypothesized that repeated infusions of CD33 CAR-NK cells would prolong remission and increase the antitumor efficacy. However, after multiple infusions of 1.8 × 10⁹ ...